Tag: biotechnology
-
U.S. Patent Awarded for Freeze-Dried Vaccine Formulation
9 September 2014. The technology making possible production and shipping of vaccines in a stable freeze-dried state received U.S. patent protection. Patent no. 8,808,710 was awarded last month by the U.S. Patent and Trademark Office to four inventors and assigned to University of Colorado. Soligenix Inc. in Princeton, New Jersey licensed the technology from University…
-
Calico, AbbVie Partner on Aging Disorder Therapies
3 September 2014. California Life Sciences LLC, better known as Calico, and the pharmaceutical company AbbVie Inc. are collaborating on discovery and commercialization of drugs for age-related diseases such as cancer and neurodegenerative disorders. The partnership, which includes building a new research center, could result in a joint investment as high as $1.5 billion. Calico,…
-
Ebola Vaccine Safety Trials Scheduled in U.S., U.K., Africa
28 August 2014. Early-stage clinical trials testing the safety of new vaccines to protect against the Ebola virus are scheduled to begin as early as next week at sites in the U.S., United Kingdom, Mali, and The Gambia in West Africa. The vaccines are being developed by National Institute of Allergy and Infectious Diseases (NIAID),…
-
Biotech, Universities to Test Hydrogel for Vocal Fold Scars
28 August 2014. BioTime Inc., a biotechnology company in Alameida, California, is partnering with researchers at University of Wisconsin and Université catholique de Louvain in Belgium to test its hydrogels for treating vocal cord scarring, a voice problem that results from injury or disease. Financial terms of the collaboration were not disclosed. Vocal folds are…
-
Extended Hemophilia Therapy Lowers Bleeding Rates in Trial
22 August 2014. Results from a late-stage clinical trial show an extended-life therapy to control hemophilia reduces rates of bleeding among patients when used as a preventive medication. The biologic tested in the trial is an extended release version of Advate, an engineered form of blood coagulant proteins made by Illinois-based drug maker Baxter International…
-
Analysis Uncovers Biotech Commercialization Bottlenecks
21 August 2014. The path from scientific discovery in an academic lab to the marketplace is rarely a straightforward process, with researchers and entrepreneurs often facing detours and delays keeping new biomedical technologies in limbo for years at a time. Those are the conclusions of faculty at Georgia Institute of Technology’s business school that studied…
-
Novartis Acquires Stake in Stem Cell Therapy Company
19 August 2014. Gamida Cell, a developer of therapies from umbilical cord stem cells, says the global pharmaceutical company Novartis is buying a 15 percent interest in the company, with an option to acquire the entire company later. The deal brings Gamida Cell, located in Jerusalem, Israel, $35 million immediately, with a total potential return…
-
Biotech, Institutes Discover Target for Multiple Tumors
14 August 2014. Researchers in the U.S. and Australia identified an enzyme found in a range of cancerous tumor cells, but not normal adult tissue, and tested an engineered antibody to fight that enzyme in tumors. The team from the biotechnology company KaloBios Pharmaceuticals Inc. in South San Francisco, California, and Monash University and Ludwig…
-
Genetically Engineered Medflies Found to Control Wild Types
13 August 2014. Researchers at the biotechnology company Oxitec Ltd. in Oxford and University of East Anglia in Norwich, both in the U.K., created a modified form of the Mediterranean fruit fly that tests show can reduce the population of this pest responsible for extensive crop damage in many parts of the world. Results of…
-
Licensing Deal Combines Genomics, Placenta Stem Cells
11 August 2014. A new licensing agreement will make available research by Celgene Cellular Therapeutics on stem cells from the placenta to Human Longevity Inc., a company specializing in genomics for age-related disorders. Financial aspects of the agreement were not disclosed, but as part of the deal, Celgene is expected to make an equity investment…